A case report in cardiovascular magnetic resonance: the contrast agent matters in amyloid
暂无分享,去创建一个
Julian D. Gillmore | James C. Moon | Stefania Rosmini | Marianna Fontana | Thomas A. Treibel | Ana Martinez-Naharro | Raymond Y. Kwong | Philip N. Hawkins | R. Kwong | J. Moon | P. Hawkins | M. Fontana | S. Rosmini | T. Treibel | J. Gillmore | A. Martinez-Naharro
[1] M. Robson,et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement , 2013, Journal of Cardiovascular Magnetic Resonance.
[2] Andrew S Flett,et al. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR , 2012, Journal of Cardiovascular Magnetic Resonance.
[3] R. Falk,et al. Cardiovascular magnetic resonance in cardiac amyloidosis. , 2005, Circulation.
[4] F. Schick,et al. Relaxivity of Gadopentetate Dimeglumine (Magnevist), Gadobutrol (Gadovist), and Gadobenate Dimeglumine (MultiHance) in Human Blood Plasma at 0.2, 1.5, and 3 Tesla , 2006, Investigative radiology.